Personalized Medicine: What Pharma Should Do To Get Ready | Diaceutics

Personalized Medicine: What Pharma Should Do To Get Ready

August 24th, 2015

Tessa Sandberg

The first class of an entrepreneurial program teaches students that change goes hand-in-hand with opportunity. At the moment, the clinical world is experiencing a revolutionary shift towards personalized medicine (PM) and so a huge opportunity is being created. But what should pharma do to capture this opportunity? Tessa Sandberg of Diaceutics examines this in ‘Personalized Medicine: What Pharma Should Do to Get Ready’ and reveals the actions and activities essential for companies who are determined to take this chance.

At the beginning of 2015, President Obama announced that the USA will invest $215 million in the 2016 budget to launch the ‘Precision Medicine Initiative’. Precision medicine, or personalized medicine as it is known outside the US, is considered to be the most promising and revolutionary health care approach of our time—an approach which aims to treat the right patient with the right drug at the right time. It is different altogether from the old ‘one-size-fits-all’ treatments where the same drug can be very successful for some patients but not for others.

An essential component of personalized medicine is diagnostic (Dx) testing, which identifies the right patient for the right drug. The diagnostic industry is growing steadily, but what does it mean for the pharmaceutical industry and how can pharma seize this personalized medicine opportunity?

Entrepreneurs can come up with brilliant ideas but the greater challenge is to make the idea become a reality. Like the entrepreneur, you may have already identified the ideas behind personalized medicine, but a lack of experience within the team, or even the whole company, means you don’t know how to move forward. Perhaps some of these scenarios sound familiar:

  • You have probably noticed that Dx development should be aligned with Rx development but how do you actually do that?
  • For pharma, partnering is an essential aspect of drug and diagnostic development and commercialization, but how do you select the most appropriate partner and what happens once you’ve made that choice?
  • If the pharma industry has developed a reputation for being ‘all about the money’, how can you show that your business is focused on providing the best for the patient?
  • With diagnostic testing being such an essential part of personalized medicine, you’ll acknowledge the link it has with laboratories, but why is that association so important?

Diaceutics is convinced that something is changing in the clinical world. We have been on top of personalized medicine since its early beginnings so we recognise the pharmaceutical industry’s need to understand diagnostic development, planning and commercialization. We are happy to share our robust insights regarding the importance and the potential impact of diagnostics in a series of articles called Personalized Medicine: What Pharma Should Do to Get Ready. These articles will cover aspects of diagnostic commercialization such as planning, communication with stakeholders, allocating budgets for development and the importance of partnering.

We hope the articles will be a useful tool for initiating discussions, creating awareness within your team about diagnostic planning and getting you ready for a future in personalized medicine.


Personalized Medicine: What Pharma Should do to get Ready Series

[php snippet=34 param=”title=Part 1 – Importance of Establishing a Robust Diagnostic Development and Commercialization Strategy on Time&id=967&useTitle=true”]
[php snippet=34 param=”title=Part 2 – Integrating and Aligning the Diagnostic Strategy with the Drug Strategy&id=966&useTitle=true”]
[php snippet=34 param=”title=Part 3 – Partnering and Managing Partnerships&id=963&useTitle=true”]
[php snippet=34 param=”title=Part 4 – The Shift Towards Patient Centricity&id=961&useTitle=true”]
[php snippet=34 param=”title=Part 5 – Pharma Communication and Education for Stakeholders&id=962&useTitle=true”]
[php snippet=34 param=”title=Part 6 – Funding a Diagnostic Test at Launch to Ensure Test Adoption&id=960&useTitle=true”]
[php snippet=34 param=”title=Part 7 – Engaging with Laboratories&id=959&useTitle=true”]
[php snippet=34 param=”title=Part 8 – Ensure Diverse Internal Capabilities in a Personalized Medicine Pharma Company&id=957&useTitle=true”]
[php snippet=34 param=”title=Part 9 – Budget Allocation for Diagnostic Development and Commercialization&id=958&useTitle=true”]


View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications